Doxoves™ - Liposomal Doxorubicin HCl, New 2mg/mL
항종양 활성을 갖는 항생물질 Doxorubicin HCl을 내포한 liposome입니다. Doxorubicin HCl을 liposome 내에 내포
시킴으로써 pharmacokinetics/pharmacodynamics(PK/PD)적인 작용이 개선됩니다.
입경이 균일하기 때문에 lot 간의 차이가 적은 고품질로서, 높은 봉입 효율을 보이도록 조제되어 있습니다.
Doxorubicin HCl이 없는 control용 liposome도 있습니다.
* Doxorubicin은, reverse transcriptase, RNA polymerase의 활성을 억제하는 항생물질입니다. Intercalation에
의해 이중 가닥 DNA에 결합하여, DNA의 복제·전사를 억제하는 것으로 생각되고 있으며, 세포 사멸을 유도합니다.
Cryo-EM of FormuMax's liposome doxorubicin HCl (F30204B-D) (Image taken by NanoImaging Services Inc.)
FormuMax has been providing custom-made formulations of liposomal doxorubicin HCl with various lipid
compositions and particle sizes. There has been an increased demand of liposomal doxorubicin
comparable to the commercial Doxil®. Now we are proudly naming our product, Doxoves®, and making it
available to you at an affordable price.
Doxoves®is manufactured to high quality with consistent lot-lot characteristics, tight particle size distribution
and high drug encapsulation efficiency. A high drug concentration of 4.0 mg/mL (40mM lipid) allows
researchers to perform experiments athigher concentrations/doses.
Doxoves® is comparable to the
commercial product Doxil® in characteristics, stability and pharmacokinetics. Cryo-TEM studies have
shown that the encapsulated doxorubicin forms the same type of rod-like structures as in Doxil®. A recent
PK study of two batches of Doxoves® demonstrated an excellent PK profile with t1/2 of 30-40hr similar to that
of Doxil®.
작성일 : 14-12-12
